Bastin Alireza, Netticadan Thomas, Abbasi Fatemeh, Rahimi Naseeb, Mahmoodi Marzieh, Alizadeh Mehdi, Movahed Ali, Momeni-Moghaddam Mohammad Amin
Clinical Research Development Center "The Persian Gulf Martyrs" Hospital, Bushehr University of Medical Sciences, Bushehr, Iran.
Department of Clinical Biochemistry, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Mol Cell Biochem. 2025 Apr 30. doi: 10.1007/s11010-025-05290-3.
Studies show that the clinical symptoms of Coronavirus disease 2019 (COVID-19) are significantly reduced by treatment with medicinal plants, including plants with strong anti-inflammatory and antioxidant properties. The use of herbal medicines and supplements is considered to be suitable due to relatively mild side effects. Resveratrol is one of the most potent plant compounds found in both medicinal and non-medicinal plants, and it has strong anti-inflammatory and antioxidant properties. Therefore, the aim of the double-blind clinical study was to investigate the effects of resveratrol consumption on biochemical markers, hematological parameters, and some inflammatory cytokines in patients with COVID-19.
A total of 44 patients with COVID-19 were randomly assigned to receive 750 mg/day of resveratrol (n = 24) orally or placebo (n = 20) for 10 days. A permuted block randomized design (block size two) was used for randomization. The biochemical markers, hematological parameters, and plasma levels of Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Interleukin-10 (IL-10), and Tumor necrosis factor-alpha (TNF-α) cytokines were measured at baseline and after 10 days.
We observed a statistically significant reduction in the C-reactive protein (CRP) (P = 0.041), Fasting blood sugar (FBS) (P = 0.002), Alkaline phosphatase (ALP) (P = 0.034), IL-1β (P = 0.011), TNF-α (P = 0.001), and White blood cell (WBC) (P = 0.043), Platelet count (PLT) (P = 0.042), Neutrophils (NUT) (P = 0.015) and an increase in Lymphocyte (LYM) (P = 0.010) in the resveratrol treated group when compared with the placebo group.
The present study demonstrated that resveratrol as an herbal supplement may be useful in reducing markers of inflammation, neutrophils, and low platelet count, as well as lowering blood glucose levels in patients with COVID-19. The trial was prospectively registered at IRCT.ir as IRCT20111119008129N13. Registration date: 2022-10-11.
研究表明,包括具有强大抗炎和抗氧化特性的植物在内,药用植物治疗可显著减轻2019冠状病毒病(COVID-19)的临床症状。由于副作用相对较轻,草药和补充剂的使用被认为是合适的。白藜芦醇是在药用和非药用植物中发现的最有效的植物化合物之一,具有强大的抗炎和抗氧化特性。因此,这项双盲临床研究的目的是调查服用白藜芦醇对COVID-19患者生化指标、血液学参数和一些炎性细胞因子的影响。
总共44例COVID-19患者被随机分配,口服750毫克/天的白藜芦醇(n = 24)或安慰剂(n = 20),为期10天。采用置换区组随机设计(区组大小为2)进行随机分组。在基线和10天后测量生化指标、血液学参数以及白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)和肿瘤坏死因子-α(TNF-α)细胞因子的血浆水平。
与安慰剂组相比,我们观察到白藜芦醇治疗组的C反应蛋白(CRP)(P = 0.041)、空腹血糖(FBS)(P = 0.002)、碱性磷酸酶(ALP)(P = 0.034)、IL-1β(P = 0.011)、TNF-α(P = 0.001)以及白细胞(WBC)(P = 0.043)、血小板计数(PLT)(P = 0.042)、中性粒细胞(NUT)(P = 0.015)有统计学显著降低,淋巴细胞(LYM)增加(P = 0.010)。
本研究表明,白藜芦醇作为一种草药补充剂,可能有助于降低COVID-19患者的炎症指标、中性粒细胞和低血小板计数,以及降低血糖水平。该试验已在IRCT.ir上进行前瞻性注册,注册号为IRCT20111119008129N13。注册日期:2022年10月11日。